Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Acetaminophen toxicity induces mitochondrial complex I inhibition in human liver tissue

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pharmacokinetics of Ferric bepectate - a new intravenous iron drug for treating iron deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Short-course vs long-course antibiotic treatment for community-acquired pneumonia: A literature review

    Research output: Contribution to journalReviewResearchpeer-review

  1. Reappraisal is an effective emotion regulation strategy in children with Tourette syndrome and ADHD

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dr. Uhre et al. Reply

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

This study investigated the influence of variations in the carboxylesterase 1 gene (CES1) on the pharmacokinetics of enalapril. Forty-three healthy, Danish, Caucasian volunteers representing different pre-defined genotypes each received 10 mg of enalapril. At specified time-points, plasma concentrations of enalapril and the active metabolite enalaprilat were measured. The volunteers were divided into six different groups according to their genetic profile of CES1: group 1 (control group, n = 16) with two CES1 copies without non-synonymous SNPs in the exons; group 2 (n = 5) with four copies of CES1; group 3 (n = 6) harbouring the G143E polymorphism; group 4 (n = 2) with three CES1 copies and increased transcriptional activity of the duplication (CES1A2); group 5 (n = 4) harbouring the CES1A1c variant; and group 6 (n = 10) with three CES1 copies and the common promoter with low transcriptional activity of the duplication. The median AUC of enalaprilat in the control group was not significantly different from any of the other five groups (297 ng/ml x h in the control group versus 310, 282, 294, 344 and 306 ng/ml x h in groups 2-6, respectively). The terminal half-life of enalaprilat was significantly longer in group 6 compared with the control group (26.7 hr versus 12.7 hr, respectively). However, this was not considered clinically relevant. In conclusion, none of the selected variations of CES1 had a clinically relevant impact on the metabolism of enalapril.

Original languageEnglish
JournalBasic & clinical pharmacology & toxicology
ISSN1742-7843
DOIs
Publication statusPublished - Jul 2017

    Research areas

  • Journal Article

ID: 51521057